Embed Size (px)
Citation preview
News release.
Amferia establishes R&D operations at AstraZeneca’s BioVentureHub 28 October 2019
Amferia, an innovative medtech company developing novel antimicrobial materials for medical devices, is now establishing operations in the BioVentureHub at AstraZeneca Gothenburg.
The move to AstraZeneca’s BioVentureHub will enable Amferia to develop its own R&D labs, as well as benefit from the valuable networking opportunities and expertise in the hub. The move also aligns well with Amferia’s long-term vision of growth and expansion within medtech and anti-infective devices in the fight against antibiotic resistance.
Amferia develops innovative medical devices to provide solutions to the global antibiotic resistance crisis. Amferia’s core focus is preventive healthcare where the goal is to provide highly efficient, anti-infective medical devices that can prevent bacterial infections, including those caused by antibiotic resistant bacteria.
Anand Rajasekharan, CEO of Amferia − “Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.”
Magnus Björsne, CEO of AstraZeneca’s BioVentureHub − “We are very happy to welcome Amferia to the BioVentureHub. Antibiotic resistance continues to be a major problem affecting people all over the world. Anand, Saba and the Amferia team are developing an innovative approach to tackling infections. They will add complementary skills and new perspectives to the collaborative innovation environment in the BioVenturehub. We look forward to see them thrive and grow!”
Dr. David Storek, Amferia’s Business Coach at Chalmers Ventures − “We consider the move to the BioVentureHub an essential step in Amferia’s development. It steps up Amferia’s presence in a most pertinent community of potential customers and collaboration partners and strengthens their ability to communicate with and learn from important stakeholders.”
= = =
About Amferia Amferia was founded in 2018 as a spin-off from Professor Martin Andersson’s Nanomaterials Lab at Chalmers University, Sweden. Amferia’s proprietary patented technology is a new and effective antibacterial material. The material consists of bioinspired and amphiphilic antibacterial polymers that target and rapidly kill bacteria upon contact, including numerous antibiotic resistant bacteria like MRSA and MDR E. Coli. The material is highly selective and targets only bacteria while being entirely non-toxic to human cells. Today, the team has transformed this concept into a first product of a preventive wound care patch for skin wound applications supported by strong scientific data. The first goal is to develop and bring this concept into the market as a preventive care for patients at risk of acquiring dangerous skin infections. Read more at www.amferia.com About AstraZeneca’s BioVentureHub AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech & medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other. For more information, see www.azbioventurehub.com = = =
For more information, please contact: Anand Kumar Rajasekharan, Chief Executive Officer, Amferia, +46 762 981238, [email protected] Jamie Smith, Chief Communications Officer, AstraZeneca BioVentureHub, +46 723 757507, [email protected] = = =
